Rapport Therapeutics to Present at 22nd Annual Morgan Stanley Global Healthcare Conference and TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule medicines for CNS disorders, has announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rapport Therapeutics (Nasdaq: RAPP), a clinical-stage biotech company developing small molecule medicines for CNS disorders, has announced its participation in two upcoming investor conferences. The company will present at:
1. The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on September 5, 2024, at 4:50 pm ET.
2. TD Cowen's 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on September 26, 2024, at 11:40 am ET.
A live and archived webcast of the Morgan Stanley Conference fireside chat will be available on the company's investor relations website. This presentation offers investors an opportunity to gain insights into Rapport Therapeutics' progress in developing innovative treatments for central nervous system disorders.
Details
News Market Reaction – RAPP
The recorded move for RAPP in the trading session of this news was -1.88%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BOSTON and SAN DIEGO, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP), a clinical-stage biotechnology company focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders, today announced that management will present at two upcoming investor conferences:
- The Morgan Stanley 22nd Annual Global Healthcare Conference in New York City on Thursday, September 5, 2024, at 4:50 pm ET.
- TD Cowen’s 4th Annual Novel Mechanisms in Neuropsychiatry Summit (Virtual) on Thursday, September 26, 2024, at 11:40 am ET.
Interested parties may access a live and archived webcast of the Morgan Stanley Conference fireside chat on the “Investors” section of the company’s website at: https://investors.rapportrx.com.
About Rapport Therapeutics
Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformational precision neuromedicines for patients suffering from central nervous system (CNS) disorders. The Company’s founders have made pioneering discoveries related to the function of receptor associated proteins (RAPs) in the brain. Their findings form the basis of Rapport’s RAP technology platform, which enables a differentiated approach to generate precision small molecule product candidates with the potential to overcome many limitations of conventional neurology drug discovery. Rapport’s precision neuroscience pipeline includes the Company’s lead clinical program, RAP-219, designed to achieve neuroanatomical specificity through its selective targeting of a RAP expressed in only discrete regions of the brain. The Company is currently advancing RAP-219 in clinical trials in focal epilepsy, peripheral neuropathic pain, and bipolar disorder. Additional preclinical and late-stage discovery stage programs are also underway, targeting CNS disorders including chronic pain and hearing disorders.
Contact
Julie DiCarlo
Head of Communications & IR
Rapport Therapeutics
jdicarlo@rapportrx.com
Source: https://www.rapportrx.com/
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.